Alexander Zwart, MD
Endocrinology, Diabetes & Metabolism · Tucson, AZNPI 1225018856
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $823 of the $1,159 with a category attached, or 71.1%. It is spread thinly across 15 manufacturers, the largest accounting for just 18.7%. Reporting peaked in 2024 at $326 and has fallen 51.6% since, to $158 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AZ, where the typical reported total is $2,225.
Across 34 payments — averaging $34.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$216
- Lilly USA, LLC$156
- Dexcom, Inc.$152
- Amgen$151
- Kyowa Kirin, Inc.$131
- Medtronic$73
- plus $280 from 9 others
Across 43 payments — averaging $279.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$12K
What the payments were for
- Food & beverage$82371%
- Education$33529%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 2 | $216 |
| Lilly USA, LLC | 3 | $156 |
| Dexcom, Inc. | 8 | $152 |
| Amgen(2 entities) | 5 | $151 |
| Kyowa Kirin, Inc. | 1 | $131 |
| Medtronic(2 entities) | 3 | $73 |
| Radius Health, Inc. | 2 | $67 |
| Corcept Therapeutics | 1 | $51 |
| Ascensia Diabetes Care US Inc. | 2 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Novo Nordisk | 1 | $25 |
| BETA Bionics, Inc. | 2 | $24 |
| Sequel Med Tech, LLC | 1 | $17 |
| Astellas Pharma US Inc | 1 | $15 |
| Insulet Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Lite system$200
- CRYSVITA$131
- MOUNJARO$123
How this compares
$1,159 in reported general payments places this provider in the 40th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IsturisaOsilodrostat Phosphate | 28 | $783,867 |
| OzempicSemaglutide | 229 | $379,426 |
| KorlymMifepristone | 17 | $225,904 |
| TrulicityDulaglutide | 66 | $116,307 |
| JardianceEmpagliflozin | 83 | $111,693 |
| MounjaroTirzepatide | 78 | $104,833 |
| FarxigaDapagliflozin Propanediol | 96 | $89,419 |
| ProliaDenosumab | 46 | $79,794 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $77,897 |
| GenotropinSomatropin | 28 | $60,961 |
| Tresiba Flextouch U-100Insulin Degludec | 75 | $58,444 |
| JanuviaSitagliptin Phosphate | 39 | $51,527 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 43 | $50,882 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $48,863 |
| MycapssaOctreotide Acetate | 11 | $43,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $25 | $413,319270 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30 | $156 | $258,227272 claims |
| Corcept TherapeuticsKorlym | $51 | $225,90417 claims |
| AmgenProlia | $151 | $79,79446 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Tucson
- Muhammad SethiTucson$670K
- Karen HerbstTucson$200K
- Nora BarsonyTucson$121K
- Maria PosadasTucson$24K
- Dorota PucykTucson$15K
- Neda EbrahimiTucson$11K
- Casey RendonTucson$9K
- Jonathan InselTucson$7K
- Roshanak HabibiTucson$7K
- Ramiro Cardenas LaraTucson$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.